Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia

References

• Dohner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Tam CS, Shanafelt TD, Wierda WG, . De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009;114:957–964.
   PubMed Web of Science ®Google Scholar
• Zenz T, Hoth P, Busch R, . TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG. Blood 2009;114(Suppl. 1): Abstract 1267.
   Google Scholar
• Oscier D, Wade R, Davis Z, . Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:1705–1712.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, . Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial. Blood 2008;112(Suppl. 1): Abstract 781.
   Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Medeiros LJ, Li Y, . Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012;119:3668–3683.
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Martinez P, Wade R, . Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:2223–2229.
   PubMed Web of Science ®Google Scholar
• Zenz T, Krober A, Scherer K, . Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322–3329.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, . Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001.
   PubMed Web of Science ®Google Scholar
• Pospisilova S, Gonzalez D, Malcikova J, ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012 Feb 2. [Epub ahead of print]
   Web of Science ®Google Scholar
• Austen B, Powell JE, Alvi A, . Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175–3182.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Hotta T, Ichikawa A, . The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158–3165.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Bottoni A, Shimizu M, . Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011;305:59–67.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Davis ZA, . A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009;23:212–214.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Oscier DG, Fitchett M, . Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720–724.
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, . Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742–751.
   PubMed Web of Science ®Google Scholar
• Grubor V, Krasnitz A, Troge JE, . Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009;113:1294–1303.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Dicker F, Schnittger S, . Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007;21:2442–2451.
   PubMed Web of Science ®Google Scholar
• Pfeifer D, Pantic M, Skatulla I, . Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007;109:1202–1210.
   PubMed Web of Science ®Google Scholar
• Kay NE, Eckel-Passow JE, Braggio E, . Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 2010;203:161–168.
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW, . Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799–804.
   PubMed Web of Science ®Google Scholar
• Zenz T, Vollmer D, Trbusek M, . TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010;24:2072–2079.
   PubMed Web of Science ®Google Scholar
• Dicker F, Herholz H, Schnittger S, . The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117–124.
   PubMed Web of Science ®Google Scholar
• el Rouby S, Thomas A, Costin D, . p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452–3459.
   PubMed Web of Science ®Google Scholar
• Pekova S, Mazal O, Cmejla R, . A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: analysis of 1287 diagnostic and 1148 follow-up CLL samples. Leuk Res 2011;35:889–898.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Tavolaro S, Marinelli M, . Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer 2011;50:263–274.
   PubMed Web of Science ®Google Scholar
• Trbusek M, Smardova J, Malcikova J, . Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703–2708.
   PubMed Web of Science ®Google Scholar
• Dittmer D, Pati S, Zambetti G, . Gain of function mutations in p53. Nat Genet 1993;4:42–46.
   PubMed Web of Science ®Google Scholar
• Bromidge T, Johnson S, Howe D. Spectrum of p53 mutations in low-grade B-cell malignancies. Leukemia 2008;22:1071–1073.
   PubMed Web of Science ®Google Scholar
• Zainuddin N, Murray F, Kanduri M, . TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011;35:272–274.
   PubMed Web of Science ®Google Scholar
• Dong HJ, Zhou LT, Zhu DX, . The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol 2011;90:709–717.
   PubMedGoogle Scholar
• Mohr J, Helfrich H, Fuge M, . DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011;117:1622–1632.
   PubMed Web of Science ®Google Scholar
• Zenz T, Habe S, Denzel T, . Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589–2597.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Sherrington PD, Stewart G, . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814–822.
   PubMed Web of Science ®Google Scholar
• Johnson GG, Sherrington PD, Carter A, . A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009;69:5210–5217.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Majid A, . A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008;22:1456–1459.
   PubMed Web of Science ®Google Scholar
• Mous R, Jaspers A, Luijks DM, . Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia 2009;23:1352–1355.
   PubMed Web of Science ®Google Scholar
• Trbusek M, Malcikova J, Smardova J, . Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 2006;20:1159–1161.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Tam C, Abruzzo LV, . Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373–380.
   PubMed Web of Science ®Google Scholar
• Schlette EJ, Admirand J, Wierda W, . p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma 2009;50:1597–1605.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Chuang EY, Davis RE, . Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428–1434.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, . Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Schetelig J, van Biezen A, Brand R, . Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008;26:5094–5100.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, . Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107:885–891.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, . Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793–798.
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Bosch F, Abrisqueta P, Villamor N, . Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578–4584.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Keating MJ, O’Brien S, . Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011;118:2062–2068.
   PubMed Web of Science ®Google Scholar
• Heit W, Bunjes D, Wiesneth M, . Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986;64:479–486.
   PubMed Web of Science ®Google Scholar
• Dyer MJ, Hale G, Hayhoe FG, . Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431–1439.
   PubMed Web of Science ®Google Scholar
• Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23:1098–1104.
   PubMed Web of Science ®Google Scholar
• Rowan W, Tite J, Topley P, . Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427–436.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452–453.
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW, . Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Pasquini MC, Gardellini A, . Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009;23:2027–2033.
   PubMed Web of Science ®Google Scholar
• Fiegl M, Erdel M, Tinhofer I, . Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 2010;21:2410–2419.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, . Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;20:1441–1445.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Cymbalista F, Leblond V, . Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: interim analysis of a phase II study of the GCLLSG and FCGCLL/MW. Blood 2011; 118(Suppl. 1): Abstract 2854.
   Google Scholar
• Ben-Bassat I, Raanani P, Gale RP. Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 2007;39:441–446.
   PubMed Web of Science ®Google Scholar
• Schetelig J, Thiede C, Bornhauser M, . Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747–2753.
   PubMedGoogle Scholar
• Khouri IF, Saliba RM, Admirand J, . Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137:355–363.
   PubMed Web of Science ®Google Scholar
• Moreno C, Villamor N, Colomer D, . Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23:3433–3438.
   PubMed Web of Science ®Google Scholar
• Dreger P, Corradini P, Kimby E, . Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21:12–17.
   PubMed Web of Science ®Google Scholar
• Dreger P, Dohner H, Ritgen M, . Allogeneic stem cell transplantation provides durable disease control in poor- risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116:2438–2447.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362–371.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, . Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Lin TS, Ruppert AS, Johnson AJ, . Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012–6018.
   PubMed Web of Science ®Google Scholar
• Lanasa MC, Andritsos L, Brown JR, . Interim analysis of EFC6663, a multicenter phase 2 study of alvocidib (flavopiridol), demonstrates clinical responses among patients with fludarabine refractory CLL. Blood 2010;116(Suppl. 1): Abstract 58.
   Google Scholar
• Chanan-Khan A, Miller KC, Musial L, . Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24:5343–5349.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, . Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Keating MJ, Wierda WG, . Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities. Blood 2007; 110(Suppl. 1): Abstreact 754.
   Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, . Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149–1159.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, . Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–496.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Krysov S, Davies AJ, . B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118:4313–4320.
   PubMed Web of Science ®Google Scholar
• Furman RR, Byrd JC, Brown JR, . CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116(Suppl. 1): Abstract 55.
   Google Scholar
• O’Brien S, Burger JA, Blum KA, . The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic Lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. Blood 2011; 118(Suppl. 1): Abstract 983.
   Google Scholar